Versant Venture Capital VI, L.P. - 10 Nov 2025 SCHEDULE 13D/A Report for Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share (GLUE)

Filing Manager: Versant Venture Capital VI, L.P.
Reporting Manager: Versant Venture Capital VI, L.P.
Security: Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share
Symbol: GLUE
Shares outstanding: 65.4M shares
Disclosed Ownership: 3.33M shares
Ownership: 5.1%
Form type: SCHEDULE 13D/A
Filing time: 12 Nov 2025, 16:13:06 UTC
Date of event: 10 Nov 2025
SEC: View on sec.gov

Reporting Managers (6)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
Versant Venture Capital VI, L.P.	5.1%	3.33M	3.33M	0	/s/Max Eisenberg	Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the GP of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P.	0001687880
Versant Ventures VI GP, L.P.	5.1%	3.33M	0	3.33M	/s/Max Eisenberg	Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the General Partner of Versant Ventures VI GP, L.P.	0001777654
Versant Ventures VI GP-GP, LLC	5.1%	3.33M	0	3.33M	/s/Max Eisenberg	Max Eisenberg/COO	0001777652
Versant Vantage I, L.P.	2.4%	1.57M	1.57M	0	/s/Max Eisenberg	Max Eisenberg/COO of Versant Vantage I GP-GP, LLC, the GP of Versant Vantage I GP, L.P., the GP of Versant Vantage I, L.P.
Versant Vantage I GP, L.P.	2.4%	1.57M	0	1.57M	/s/Max Eisenberg	Max Eisenberg/COO of Versant Vantage I GP-GP, LLC, the General Partner of Versant Vantage I GP, L.P.
Versant Vantage I GP-GP, LLC	2.4%	1.57M	0	1.57M	/s/Max Eisenberg	Max Eisenberg/COO